GlassScriptPhysician profile
Jose M Madamba
NPI 1275637712
$4,762.46
in general payments reported to CMS, 2019-2025
15 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,271 · 2020: $422 · 2021: $734 · 2022: $337 · 2023: $257 · 2024: $367 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,370.42 | 2019-2024 | Farxiga |
| Abbvie INC. | $758.22 | 2019-2025 | |
| Novo Nordisk INC | $596.07 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $447.28 | 2019-2022 | |
| Amarin Pharma, INC. | $368.24 | 2019-2021 | |
| Dexcom, INC. | $266.56 | 2023-2024 | Dexcom G7 Gss (161) |
| Aimmune Therapeutics, INC. | $249.98 | 2025 | Zenpep |
| Horizon Therapeutics Plc | $169.06 | 2019-2023 | Krystexxa |
| Sunovion Pharmaceuticals INC. | $124.71 | 2019 | |
| Esperion Therapeutics, INC. | $122.89 | 2021 | |
| Merck Sharp & Dohme LLC | $111.13 | 2019 | |
| Lilly USA, LLC | $85.09 | 2024 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $46.06 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.35 | 2022 | |
| Astellas Pharma US INC | $17.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Madamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.